Troy A. Ignelzi - 08 Sep 2021 Form 4 Insider Report for Karuna Therapeutics, Inc.

Role: Chief Financial Officer
Signature: /s/ Troy Ignelzi
Issuer symbol: N/A
Transactions as of: 08 Sep 2021
Net transactions value: -$1,081,846
Form type: 4
Filing time: 10 Sep 2021, 16:58:56 UTC
Previous filing: 23 Aug 2021
Next filing: 10 Nov 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KRTX	Common Stock	Options Exercise	$64,400	+7,000	+39%	$9.20^*	25,000	08 Sep 2021	Direct
transaction	KRTX	Common Stock	Sale	$813,120	-7,000	-28%	$116.16	18,000	08 Sep 2021	Direct	F1, F2
transaction	KRTX	Common Stock	Options Exercise	$5,520	+600	+3.3%	$9.20^*	18,600	08 Sep 2021	Direct
transaction	KRTX	Common Stock	Sale	$72,606	-600	-3.2%	$121.01	18,000	08 Sep 2021	Direct	F1
transaction	KRTX	Common Stock	Options Exercise	$4,600	+500	+2.8%	$9.20^*	18,500	09 Sep 2021	Direct
transaction	KRTX	Common Stock	Sale	$60,025	-500	-2.7%	$120.05	18,000	09 Sep 2021	Direct	F1
transaction	KRTX	Common Stock	Options Exercise	$17,480	+1,900	+11%	$9.20^*	19,900	10 Sep 2021	Direct
transaction	KRTX	Common Stock	Sale	$228,095	-1,900	-9.5%	$120.05	18,000	10 Sep 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KRTX	Option (right to buy)	Options Exercise	$0	-7,000	-3.7%	$0.000000	182,725	08 Sep 2021	Common Stock	7,000	$9.20	Direct	F3
transaction	KRTX	Option (right to buy)	Options Exercise	$0	-600	-0.33%	$0.000000	182,125	08 Sep 2021	Common Stock	600	$9.20	Direct	F3
transaction	KRTX	Option (right to buy)	Options Exercise	$0	-500	-0.27%	$0.000000	181,625	09 Sep 2021	Common Stock	500	$9.20	Direct	F3
transaction	KRTX	Option (right to buy)	Options Exercise	$0	-1,900	-1%	$0.000000	179,725	10 Sep 2021	Common Stock	1,900	$9.20	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021.
F2	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $116.11 to $116.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3	This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter.